

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
October 23, 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Opiant Pharmaceuticals, Inc.**

**File No. 1-38193 - CF#35558**

---

Opiant Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on October 13, 2017.

Based on representations by Opiant Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.5	through October 13, 2027
Exhibit 10.6	through October 13, 2027
Exhibit 10.7	through October 13, 2022
Exhibit 10.9	through October 13, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary